Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is expected to reach USD14689.31 million in 2026, growing at a CAGR of 10.02% during the forecast period, owing to increasing demand for innovative drugs and novel technologies for the treatment of Non-Hodgkin’s lymphomas (NHL). Improved diagnostic techniques to detect NHL are expected to push the demand for Non-Hodgkin Lymphoma (NHL) market. Furthermore, patent expiry of standard drugs, especially in untapped market is projected to provide profitable growth opportunities for the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market in upcoming years. Also, extensive R&D activities and the US Food and Drug Administration’s approval for chronic lymphocytic leukemia therapy drugs are serving as major growth drivers for the market.
Non-Hodgkin’s lymphoma (NHL) is a type of blood cancer that originates in white blood cells called lymphocytes, which are part of the body’s immune system. It is generally located at lymph nodes but if not treated on time, it might spread to the entire lymphatic system.
The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market can be segmented based on type of therapy, cell type, drug type, distribution channel, company and region. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, hospital pharmacies held the largest market share in 2020 and is estimated to maintain its leading position in the market in the next five years as well, because these therapeutic drugs are mostly dispensed in hospital pharmacies for the hospitalized patients in order to treat them. In terms of cell type, the market is fragmented into B-cell Lymphomas and T-cell Lymphomas. B-cell Lymphomas is the dominant cell type which can be attributed to the fact that B-cell Lymphomas accounts for the majority of Non-Hodgkin Lymphoma cases across the globe. On the other hand, there are smaller number of patients with T-cell Lymphoma as compared to B-cell Lymphomas.
Regionally, North America dominated the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market in 2020 and is further expected to hold its dominance during the forecast period. High prevalence of Non-Hodgkin lymphoma (NHL) and availability of advanced treatments in the region are acting as key growth drivers for the market. However, Asia-Pacific is anticipated to register the fastest CAGR during the forecast period owing to rising awareness and prevalence of Non-Hodgkin lymphoma (NHL) in the region.
Major companies operating in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Novartis AG, Eli Lilly and Company., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc., among others. The market players are focusing on R&D activities to enhance their product portfolios and strengthen their position in global market. Besides, large pharmaceutical companies are adopting strategies such as collaborations and acquisitions to further bolster their status in the Non-Hodgkin’s lymphoma therapeutics market. Also, strong product pipeline of the top players operating in the market, launch of new therapies along with commercialization of new products are other factors which are further expected to drive growth in the forthcoming years.
Years considered for this report:
- Historical Years: 2016-2019
- Base Year: 2020
- Estimated Year: 2021
- Forecast Period: 2022-2026
Objective of the Study:
- To analyze the historical growth in the market size of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market from 2016 to 2020.
- To estimate and forecast the market size of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market from 2021 to 2026 and growth rate until 2026.
- To classify and forecast the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market based on type of therapy, cell type, drug type, distribution channel, company and regional distribution from 2021 to 2026 and growth rate until 2026.
- To identify drivers and challenges for the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market.
- To identify and analyze the profile of leading players operating in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the companies which could not be identified due to the limitations of secondary research.
The publisher calculated the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market size by using a bottom-up approach, where data for various end-user industries and its application across various product types were recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used.
Key Target Audience:
- Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers, companies/partners and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, industry associations, forums and alliances related to Non-Hodgkin Lymphoma (NHL) therapeutics
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as Non-Hodgkin Lymphoma (NHL) Therapeutics manufacturing companies, end-users etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.
Report Scope:
In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy:
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Stem Cell Transplant
- Others
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Cell Type:
- B-cell Lymphomas
- T-cell Lymphomas
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Drug Type:
- Revlimid
- Rituxan
- Keytruda
- Imbruvica
- Opdivo
- Others
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
- Company Profiles: Detailed analysis of the major companies present in global Non-Hodgkin Lymphoma (NHL) therapeutics market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.
Please note: With the Enterprise license, the PDF product is printable and editable and comes with a market data excel sheet.
What is the estimated value of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market?
What is the growth rate of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market?
What is the forecasted size of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market?
Who are the key companies in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 117 |
| Published | August 2021 |
| Forecast Period | 2016 - 2026 |
| Estimated Market Value ( USD
| USD 5628.97 Million |
| Forecasted Market Value ( USD
| USD 14689.31 Million |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca PLC
- Baxter International Inc.
- Bayer AG
- Novartis AG
- Eli Lilly and Company.
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Janssen Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi S.A.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
